KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Cash from Financing Activities (2016 - 2025)

Nektar Therapeutics (NKTR) has 16 years of Cash from Financing Activities data on record, last reported at $141.7 million in Q3 2025.

  • For Q3 2025, Cash from Financing Activities rose 1089723.08% year-over-year to $141.7 million; the TTM value through Sep 2025 reached $142.0 million, up 237.66%, while the annual FY2024 figure was $42.1 million, 140293.33% up from the prior year.
  • Cash from Financing Activities reached $141.7 million in Q3 2025 per NKTR's latest filing, up from $211000.0 in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $141.7 million in Q3 2025 and bottomed at $7000.0 in Q1 2025.
  • Average Cash from Financing Activities over 5 years is $13.9 million, with a median of $339000.0 recorded in 2022.
  • The widest YoY moves for Cash from Financing Activities: up 1089723.08% in 2025, down 99.98% in 2025.
  • A 5-year view of Cash from Financing Activities shows it stood at $2.6 million in 2021, then plummeted by 95.96% to $103000.0 in 2022, then tumbled by 88.35% to $12000.0 in 2023, then skyrocketed by 591.67% to $83000.0 in 2024, then soared by 170595.18% to $141.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Financing Activities were $141.7 million in Q3 2025, $211000.0 in Q2 2025, and $7000.0 in Q1 2025.